Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Showing results for

Proceeds to fund the advancement of the company’s lead programme, REA-001, a first-in-class monoclonal antibody that potently and selectively depletes pathogenic T cells for use in a range of autoimmune diseases. The company is progressing a pipeline of antibody-based drugs to deliver transformational changes in the treatment of autoimmune diseases by depleting pathogenic T-cell populations to drive deeper and more durable clinical responses. Iain McGill has been appointed as Independent Chair, and Dhaval Patel has been appointed as Independent Director

Newly inked strategic collaboration between Entelo Bio and Atrogi to advance the future of human physical resilience

This partnership brings together Entelo Bio's groundbreaking isoform-resolved AI discovery platform and Atrogi's clinical-stage expertise in muscle-targeted metabolic medicine.

U-Ploid Biotechnologies win Technology Excellence Award at the 2026 Oxfordshire Business Awards (OXBA)

The BioEscalator was delighted to attend the awards evening as guests of The Oxford Science Park. The evening was made even more special by BioEscalator tenant U-Ploid Biotechnologies taking home the Technology Excellence Award. Congratulations to the entire team on this well-deserved recognition of their innovative work and achievements.

Re-Aim Therapeutics launches with £7m seed financing

Proceeds to fund the advancement of the company’s lead programme, REA-001, a first-in-class monoclonal antibody that potently and selectively depletes pathogenic T cells for use in a range of autoimmune diseases. The company is progressing a pipeline of antibody-based drugs to deliver transformational changes in the treatment of autoimmune diseases by depleting pathogenic T-cell populations to drive deeper and more durable clinical responses. Iain McGill has been appointed as Independent Chair, and Dhaval Patel has been appointed as Independent Director

Infinitopes appoints Immuno-Oncology Pioneer Jo Brewer as Chief Scientific Officer (CSO) to advance therapeutic pipeline From clinical to commercialisation

Infinitopes, a biotechnology company developing novel and precision immunotherapy, announces the appointment of Jo Brewer, PhD, as Chief Scientific Officer and interim Chief Operating Officer.

Entelo Bio selected as one of 20 global teams to pioneer AI target discovery in ALS

Entelo Bio has been named one of 20 global winners of the Longitude Prize on ALS, receiving funding and access to one of the world’s largest ALS datasets to support AI-driven drug target discovery. In this interview, the Oxford spinout shares how the award will accelerate its platform development, collaborative research, and expansion into neuromuscular disease.

Entelo Bio raises $4M to transform human physical resilience

Entelo Bio, an AIxBio company focused on the biology of movement and ageing, emerges from stealth today with a total of $4 million in funding, led by Ananda Impact Ventures, with participation from The Creator Fund and US and European bio- and tech-focused angels.

Infinitopes: Preventing Cancer Recurrence

Infinitopes has been featured in a recent blog post by VC Amplify Partners, highlighting its work to prevent cancer recurrence and its approach to advancing precision cancer vaccines.

U-Ploid Biotechnologies launches collaborative research study with San Diego Fertility Center and Nova Genomics

U-Ploid Biotechnologies has initiated a new collaborative research study with San Diego Fertility Center (SDFC) and Nova Genomics, marking an important translational step in the company’s programme to address the biological causes of age-related infertility.

BiotechTV talks to clinical-stage tenant Infinitopes on its second BioEscalator visit

On its recent visit to Oxford, leading biotech sector commentator Biotech TV had a fascinating and wide-ranging conversation with Dr Jonathan Kwok, the CEO of BioEscalator tenant Infinitopes.

U-Ploid Biotechnologies appoints Tim Stonehouse as Head of Regulatory Affairs

U-Ploid Biotechnologies (U-Ploid), an Oxford-based biotechnology company pioneering first-in-class therapeutics for reproductive health, today announced the appointment of Tim Stonehouse as the company’s first in-house Head of Regulatory Affairs.

Infinitopes expands seed financing to $35 Million to accelerate clinical development of precision cancer vaccine

Financing co-led by Octopus Ventures and new investor Amplify Bio. Company readies its first-in-human clinical trial of ITOP1, a precision cancer vaccine designed to prevent recurrence in oesophageal cancer.

U-Ploid Biotechnologies to present five scientific abstracts at Fertility 2026

U-Ploid Biotechnologies, a biotechnology company developing next-generation reproductive therapeutics to address age-related fertility decline, today announced that five scientific abstracts have been accepted for presentation at Fertility 2026 in Edinburgh. The presentations take place today, 8 January 2026.

Oxford Cancer Analytics graduates from the BioEscalator

In 2022, Oxford Cancer Analytics was voted the company Most Likely to be a Unicorn at that year’s BioEscalator Pitch Battle. Fast forward three years, and the company is well along its growth trajectory. OXcan has graduated from our facility as a fast-scaling diagnostics company, leveraging advanced proteomics and machine learning to develop innovative tests for earlier and more accurate assessment of lung diseases.

Akimbo Bio crosses the bridge from academia to industry as it joins the BioEscalator

The BioEscalator is pleased to welcome Akimbo Bio to its community of innovative bioscience start-ups. Co-founded by two Oxford researchers, the company is developing a next-generation immunotherapy platform that leverages intelligent receptor crosstalk to enhance both the efficacy and safety of cancer treatments.

Spectre Bio moves from computation to the lab as it joins the BioEscalator

The BioEscalator is delighted to welcome Spectre Bio to its start-up community. The company joins us as it transitions from computational research to laboratory-based development, bringing an exciting new immunomodulatory platform to the BioEscalator ecosystem.

Icosphere Biosciences appoints Dr John Beadle as Non-Executive Director

Dr Beadle brings a remarkable track record of leading biotechnology companies, guiding teams from early discovery through to successful clinical translation.

U-Ploid Biotechnologies wins Femtech competition award at the Carlos Simón Foundation for research in women’s health

U‑Ploid, a biotechnology company developing first-in-class therapeutics to tackle age-related infertility, has been awarded the Femtech Competition Award at the Femtech Pitch Showcase & Competition organised by the Carlos Simón Foundation for Research in Women’s Health, a leading institution advancing scientific excellence in reproductive medicine.

Oxford Cancer Analytics secures new space at Inventa to accelerate diagnostic innovation

Oxford Cancer Analytics (OXcan), a fast-scaling diagnostics company, has committed to a new lease of 2,400 square feet at Mission Street and BGO’s Inventa building in Oxford’s West End. OXcan is continuing its growth trajectory, moving from the BioEscalator to Inventa and joining a growing number of innovation companies in the emerging central cluster.

U-Ploid presents first Lyvanta™ data demonstrating reduction of aneuploidy in aged oocytes at ASRM 2025

U-Ploid is today presenting its first scientific abstract, “Preclinical testing of a novel therapeutic for reduction of aneuploidy in oocytes,” at the 2025 American Society for Reproductive Medicine (ASRM) Annual Meeting in San Antonio, Texas. The study showcases preclinical data on Lyvanta™ (UP-085), a novel therapeutic designed to reduce chromosome segregation errors in oocytes associated with maternal age.

Exogene Graduates from the BioEscalator

We are delighted to celebrate the graduation of Exogene as it transitions from the BioEscalator to its new home at the Wood Centre for Innovation.

Load More

Similar stories